Skip to main content

Table 1 The general characteristic of the included studies

From: Comparative efficacy and safety of different hemostatic methods in total hip arthroplasty: a network meta-analysis

Study Sample size Comparators Study design Male, % Mean age Bone cement Dose
Benoni 2000 40 (20/20) IV TXA/C RCT 42.5 69.5/68 Cemented 10 mg/kg TXA
Ekbäck 2000 40 (20/20) IV TXA/C RCT 50 66.4/65.6 Cemented 10 mg/kg TXA
Ido 2000 40 (20/20) IV TXA/C RCT NS NS Cemented 1000 mg TXA
Husted 2003 40 (20/20) IV TXA/C RCT 32.5 65/67 Cementless or hybird 10 mg/kg TXA
Lemay 2004 39 (20/19) IV TXA/C RCT 64.1 59.7/53.6 Cemented or cementless 10 mg/kg TXA
Garneti 2004 50 (25/25) IV TXA/C RCT NS 67.6/69.6 Cemented 10 mg/kg TXA
Yamasaki 2004 40 (20/20) IV TXA/C RCT 67.5 55.5/61.2 Cementless 1 g TXA
Johansson 2005 100 (47/53) IV TXA/C RCT 43 69/68 Cemented 15 mg/kg TXA
Niskanen 2005 39 (19/20) IV TXA/C RCT 33.3 66/65 Cemented 10 mg/kg TXA
Claeys 2007 40 (20/20) IV TXA/C RCT 30 73/68 Hybrid 15 mg/kg TXA
Rajesparan 2009 73 (36/37) IV TXA/C RCT 35.6 67.5/67.7 Cemented, cementless or Hybrid 1 g TXA
Kazemi 2010 64 (32/32) IV TXA/C RCT 67.2 46.6/45.4 Cementless 15 mg/kg TXA
Singh 2010 42 (21/21) IV TXA/C RCT 45.2 69/73 Cemented or cementless 10 mg/kg TXA
McConnell 2011 66 (22/22/2) IV TXA/FS/C RCT 31.8 NS Cemented 10 mg/kg TXA/10 ml FS
Malhotra 2011 50 (25/25) IV TXA/C RCT 44 52.6/54.7 Cementless 15 mg/kg TXA
Clave 2012 70 (37/33) IV TXA/C RCT 35.7 69/73 Cementless 1 g TXA
Norio 2012 117 (95/22) IV TXA/C RCT 17.9 64.4/60.2 Cementless 1 g TXA
Falez 2013 69 (31/38) FS/C RCT NS NS Cementless 10 ml FS
Lassen 2006 69 (33/36) FS/C RCT 39.1 67.1/63.1 Cemented or cementless NS
Mawatari 2006 100 (50/50) FS/C RCT NS 60/60 Cementless 10 ml FS
Randelli F 2013 70 (35/35) FS/C RCT 41.2 63.1/64.2 Cementless 10 ml FS
Wang 2003 81 (38/43) FS/C RCT 54.2 66.9/67.8 NS 10 ml FS
Xie 2016 140 (70/70) IV TXA/T TXA RCT 45 59.5/62.2 Cementless 1.5g IV TXA/3g T TXA
Wei 2014 303 (100/102/101) IV TXA/T TXA/C RCT 37.3 63.6/60.2/63.9 Cementless 3g IV TXA/3g T TXA
North 2016 139 (70/69) IV TXA/T TXA RCT 55.5 64.1/65.7 Cementless 2g IV TXA/2 g T TXA
Zhang 2016 75 (25/25/25) IV TXA/T TXA/C RCT 52 44.5/44.3/43.4 Cementless 1g IV TXA/1 g T TXA
Martin 2013 50 (25/25) T TXA/C RCT 38.7 62.9/63.9 Cemented 2g T TXA
Alshryda 2013 161 (80/81) T TXA/C RCT 45.9 66/63 Cementless NS
Yue 2014 101 (52/49) T TXA/C RCT 52.1 60.9/63.7 Cementless 3 g T TXA
Yi 2016 100 (50/50) IV TXA/C RCT 53 54/56.6 NS 15 mg/kg TXA
Lee 2013 68 (34/34) IV TXA/C RCT NS 51.4/52.8 Cementless 15 mg/kg TXA
Benoni 2001 38 (18/20) IV TXA/C RCT 50 66/68 Cemented 10 mg/kg TXA
  1. IV intravenous, T topical, TXA tranexamic acid, C control, FS fibrin sealant, NS not stated, RCT randomized controlled trials